{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T00:18:56Z","timestamp":1777767536248,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T00:00:00Z","timestamp":1252540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,9,10]],"date-time":"2009-09-10T00:00:00Z","timestamp":1252540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"abstract":"<jats:p>Twelve clinical and 102 fecal isolates from healthy carriers of Clostridium perfringens type A were tested for virulence in juvenile, outbred NMRI mice (intramuscular route). There were marked differences (up to 1,000-fold) in virulence among strains of both groups of isolates. On average, clinical isolates were not more virulent than fecal isolates. Fresh epinephrine (10 \u03bcg\/mouse and given concurrently with bacterial inocula) significantly augmented virulence. The murine model of Hill and Osterhout for experimental gas gangrene yielded reproducible results. Myelosuppressed (cyclophosphamide-pretreated) mice were somewhat more susceptible to C perfringens as contrasted with mice that had been pretreated with either carrageenan type II or with zymosan. The murine virulence of C. perfringens was enhanced significantly by Escherichia coli.<\/jats:p>","DOI":"10.1159\/000238890","type":"journal-article","created":{"date-parts":[[2009,9,11]],"date-time":"2009-09-11T09:12:33Z","timestamp":1252660353000},"page":"426-435","source":"Crossref","is-referenced-by-count":4,"title":["Virulence of Clinical and Fecal Isolates of Clostridium perfringens Type A for Outbred NMRI Mice"],"prefix":"10.1159","author":[{"given":"Walter H.","family":"Traub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dierk","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,9,10]]},"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/238890","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000238890","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:41:58Z","timestamp":1777477318000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000238890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,10]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000238890","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"value":"0009-3157","type":"print"},{"value":"1421-9794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,10]]}}}